Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H31N3O5 |
Molecular Weight | 417.4986 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O
InChI
InChIKey=HHHKFGXWKKUNCY-FHWLQOOXSA-N
InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1712267Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7700063 | https://www.ncbi.nlm.nih.gov/pubmed/1532534
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1712267
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7700063 | https://www.ncbi.nlm.nih.gov/pubmed/1532534
Cilazapril (Vascace and Dynorm are brand names in a number of European countries) is an angiotensin converting enzyme (ACE; kininase II) inhibitor. It competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Cilazapril is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. The half-life (30–50 hours) of cilazapril allows for once daily dosing unless the hypertension is severe. Cilazapril is used for the treatment of hypertension, congestive heart failure, post-myocardial infarction, and some other indications. Adverse events were mostly observed within the first 8-16 weeks of treatment, with headache, dizziness, fatigue, nausea, cough and chest pain being the most frequent.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8869081 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Vascace Approved UseVascace is used to treat the following: - High blood pressure (hypertension) - Chronic (long-term) heart failure.
It works by making your blood vessels relax and widen. This helps to lower your blood pressure. It also makes it easier for your heart to pump blood around your body if you have chronic heart failure. |
|||
Primary | Vascace Approved UseVascace is used to treat the following: - High blood pressure (hypertension) - Chronic (long-term) heart failure.
It works by making your blood vessels relax and widen. This helps to lower your blood pressure. It also makes it easier for your heart to pump blood around your body if you have chronic heart failure. |
PubMed
Title | Date | PubMed |
---|---|---|
Cardiovascular effects of the new angiotensin-converting-enzyme inhibitor, cilazapril, in anesthetized and conscious dogs. | 1986 Jan-Feb |
|
Cilazapril prevents hypertension in spontaneously hypertensive rats. | 1986 May-Jun |
|
A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor. | 1989 |
|
Anti-ischemic effects of cilazapril in patients with both hypertension and angina pectoris. Preliminary report of a pilot study. | 1991 |
|
Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. | 1992 Nov |
|
Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors. | 1995 Dec |
|
[Follow-up of patients with chronic aortic valve insufficiency with ACE inhibitor therapy]. | 1997 Dec |
|
Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy. | 2004 |
|
[A prospective study on the cough mechanism induced by angiotensin-converting enzyme inhibitors in patients with hypertension]. | 2004 Sep |
|
Impact of cilazapril on fibrinolytic system in hypertensive patients. | 2008 Jan |
Sample Use Guides
Swallow each tablet with a drink of water. It does not matter what time of day you take yablet. However, always take it around the same time. Tablet may be taken before or after a meal.
High blood pressure (hypertension): The usual starting dose for adults is 1 mg per day.
Chronic heart failure: The usual starting dose is 0.5 mg per day.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C09BA08
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
||
|
WHO-VATC |
QC09AA08
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
||
|
WHO-ATC |
C09AA08
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
||
|
WHO-VATC |
QC09BA08
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
||
|
NCI_THESAURUS |
C247
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
56330
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
21102
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | RxNorm | ||
|
D017315
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
CHEMBL515606
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
C76134
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
641
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
5675
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
CILAZAPRIL
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
DB01340
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
8Q9454114Q
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
6459
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
DTXSID1048629
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
m3545
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | Merck Index | ||
|
88768-40-5
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
3698
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
SUB23211
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY | |||
|
SUB06265MIG
Created by
admin on Sat Dec 16 17:02:02 UTC 2023 , Edited by admin on Sat Dec 16 17:02:02 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD